Posted by Michael Wonder on 05 Jun 2024
uniQure receives FDA regenerative medicine advanced therapy designation for investigational gene therapy AMT-130 in Huntington’s disease
3 June 2024 - Designation based on 24 month interim Phase 1/2 clinical data for AMT-130 announced in December 2023.
uniQure today announced that the US FDA has granted regenerative medicine advanced therapy designation for its investigational gene therapy AMT-130 for the treatment of Huntington’s disease.
